by Clinical Neuropsychologist Online | Friday, August 2, 2024 | Dementia
Abstract INTRODUCTION Triggering receptor expressed on myeloid cells 2 (TREM2) agonists are being clinically evaluated as disease-modifying therapeutics for Alzheimer’s disease. Clinically translatable pharmacodynamic (PD) biomarkers are needed to confirm drug...
by Clinical Neuropsychologist Online | Thursday, August 1, 2024 | Dementia
Abstract INTRODUCTION We disclosed amyloid positron emission tomography (PET) results in individuals with subjective cognitive decline (SCD) and studied patient experiences and outcomes over a 6-month period. METHODS Fifty-seven participants from the Subjective...
by Clinical Neuropsychologist Online | Thursday, August 1, 2024 | Dementia
Abstract INTRODUCTION In Down syndrome (DS), white matter hyperintensities (WMHs) are highly prevalent, yet their topography and association with sociodemographic data and Alzheimer’s disease (AD) biomarkers remain largely unexplored. METHODS In 261 DS adults...
by Clinical Neuropsychologist Online | Tuesday, July 30, 2024 | Dementia
Abstract The COVID pandemic has shown that when the research community comes together, we can conquer the most complex biomedical challenges. Collaboration and teamwork among federal agencies, private organizations, and researchers have been crucial in the development...
by Clinical Neuropsychologist Online | Tuesday, July 30, 2024 | Dementia
Abstract INTRODUCTION The degeneration of cortical layers is associated with cognitive decline in Alzheimer’s disease (AD). Current therapies for AD are not disease-modifying, and, despite substantial efforts, research and development for AD has faced formidable...
